Buscar
Bicycle Therapeutics PLC
BCYCAñadir a la lista de seguimiento
4.350USD
+0.140+3.33%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
218.67MCap. mercado
PérdidaP/E TTM
Más Datos de Bicycle Therapeutics PLC Compañía
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Información de Bicycle Therapeutics PLC
Símbolo de cotizaciónBCYC
Nombre de la empresaBicycle Therapeutics PLC
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoLee (Kevin)
Número de empleados305
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 23
DirecciónBlocks A & B, Portway Building
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCB21 6GS
Teléfono11441223261503
Sitio Webhttps://www.bicycletherapeutics.com/
Símbolo de cotizaciónBCYC
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoLee (Kevin)
Ejecutivos de Bicycle Therapeutics PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
758.00
-300.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alethia R. Young, M.D.
Ms. Alethia R. Young, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bicycle Therapeutics PLC?
Los cinco principales accionistas de Bicycle Therapeutics PLC son: Dr. Kevin Lee, Ph.D.
¿Cuántas instituciones poseen acciones de Bicycle Therapeutics PLC (BCYC)?
A fecha de 2026Q1, 250 instituciones poseen acciones de Bicycle Therapeutics PLC, con un valor de mercado combinado de aproximadamente 33.87M, lo que representa el 67.23% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -23140757.00.